

Cancer Therapy Evaluation Program Adverse Event Reporting System (CTEP-AERS)

Shanda Finnigan, MPH, RN, CCRC
Associate Branch Chief, Operations and Informatics Branch
CTEP, DCTD, NCI

Learning Objectives

State the main features of CTEP-AERS:

- Why retire AdEERS?
- Updated ‘Look and Feel’
- Pre-submission evaluation/rules engine
 - Verbatim terms
- SAE Report Recipients
- SAE Report Amendments

Why the switch to CTEP-AERS?

- Compliant with the FDA Final Rule
- Anticipated to save time and reduce workload
- More user-friendly and incorporates the large body of community input received during the development of caAERS

Updated 'look and feel'

- Color scheme
- Auto-complete fields
- Some AdEERS pages combined

AdEERS Color Scheme

Adverse Event Expedited Reporting System - Microsoft Internet Explorer

Address: https://ctapps-ctep.nci.nih.gov/openapps_10beta/pdorder_sec_srlq_ssb.html

Adverse Events (CTC)

NCI Protocol No.: GOG-0233 (CTCAE v3.0) -- Utility of Preoperative FDG-PET/CT and Ferumoxtran-10 MRI Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients with Locoregionally Advanced (IB2, IIA>/= 4 cm, IIB-IVA) Carcinoma of the Cervix

Adverse Event: Grade:

Category:

Adverse Event:

Other Adverse Event (specify):

Grade:

Hospitalization or prolongation of hospitalization:

Is Primary AE?:

AE Start Date (MM/DD/YYYY):

AE End Date (MM/DD/YYYY):

Comments:

Save Delete Clear New

Items labeled in BOLD are Mandatory. Report cannot be submitted without completing these fields

CTEP-AERS Color Scheme

CTEP-AERS

Report Adverse Events | Manage Reports

1. Reporter 2. Adverse Events 3. Describe Event 4. Course Cycle 5. Study Interventions 6. Subject Details 7. Other Causes 8. Labs 9. Attribution 10. Additional Info 11. Review & Submit

Ticket Number: 258807

Subject: 00703

Study: GOG-0233 Utility of Preoperative FDG-PET/CT Scanning Prior to Definitive Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients with Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA>/= 4 cm, IIB-IVA or Extension) (Grade 1 Endometrial Carcinoma, Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma Any Grade) and Grade 1 or 2 Endometrial Carcinoma, Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma Extension or Confined to Endometrial Cervix

Cancer/Cycle: TAC1 (CT) 20x FD - 1 to 80 min prior to FDG and Site immediately before FDG

Adverse Events

Instructions: Complete the required fields and add any additional information for each adverse event included in the report.

Anemia test, Grade 4 (Primary)

Verbatim text:

Grade:

- 1: Hemoglobin (Hgb) <6.5 - 10.0 g/dL; <6.5 - 8.0 mmol/L; <6.5 - 100 g/L
- 2: High <10.0 - 8.0 g/dL; <6.0 - 4.9 mmol/L; <100 - 80g/L
- 3: High <8.0 g/dL; <4.9 mmol/L; <80 g/L; transfusion indicated
- 4: Life-threatening consequences; urgent intervention indicated
- 5: Death

Start date: End date:

Did AE cause hospitalization?

Outcome:

- Death
- Hospitalization - Initial or prolonged
- Life-threatening
- Disability or Permanent Damage
- Complicated Anomaly Birth Defect
- Required Intervention to Prevent Permanent Impairment/Damage (Device)
- Other Serious (Important Medical Event)

Save & Back Save Save & Continue

Updated 'look and feel' (continued)

- Auto-complete fields

The screenshot displays the CTEP AERS (Cancer Therapy Evaluation Program Adverse Event Reporting System) interface. At the top, the National Cancer Institute logo and name are visible, along with the text "at the National Institutes of Health" and the website "www.cancer.gov". The main header features the "CTEP AERS" logo and a "Help" button. Below the header, there are navigation tabs for "Report Adverse Events" and "Manage Reports", and a "Adverse Events" button. The current step in the process is "1. Study, Subject & Course/Cycle", followed by "2. Adverse Events" and "3. Review and Report".

The main content area is titled "Select study, subject, and course/cycle/intervention". It includes instructions: "Select the study, subject, and course or cycle associated with the adverse events that you wish to report." Below the instructions, there are several fields with auto-complete dropdown menus:

- * Study**: A text input field containing "a01".
- * Subject ID**: A dropdown menu showing "(A011104) Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer".
- * Confirm Subject ID**: A dropdown menu showing "(A011106) ALTERNate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study".
- * Organization**: A dropdown menu showing "(A011202) A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy".
- * Course/Cycle/Intervention**: A dropdown menu showing "Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy".

Each dropdown menu has a small "X" icon to clear the selection. At the bottom right of the form, there is a green "Continue" button with a right-pointing arrow.

At the bottom of the page, there are links for "CONTACT US", "PRIVACY NOTICE", "DISCLAIMER", "ACCESSIBILITY", and "APPLICATION SUPPORT". Logos for the National Cancer Institute and USA.gov are also present.

Pre-submission Evaluation

- CTEP-AERS Rules engine
 - Protocol-specific AE reporting level (i.e., AE Table)
 - Protocol-specific exceptions (PSEs) to expedited reporting
 - e.g., Specific Protocol Exceptions to Expedited Reporting (SPEER), etc.
- Action/No Action Recommendations
 - Feedback prior to report completion/submission
 - Limitations
 - Override
- Anticipated to reduce over-reporting

Pre-submission Evaluation (continued)

Step 1: Identify the study, subject ID, treating institution, treatment course

The screenshot displays the CTEP AERS (Cancer Therapy Evaluation Program Adverse Event Reporting System) web interface. The header includes the National Cancer Institute logo and the text 'National Cancer Institute' on the left, and 'at the National Institutes of Health | www.cancer.gov' on the right. The main navigation bar features 'Report Adverse Events' and 'Manage Reports' buttons. Below this, a progress indicator shows three steps: '1. Study, Subject & Course/Cycle', '2. Adverse Events', and '3. Review and Report', with the first step being the active one. The main content area is titled 'Select study, subject, and course/cycle/intervention' and contains the following fields:

- * Study:** A dropdown menu with the selected value '(A031203) Randomized Phase II Study Comparing Cabozantinib (NSC #761)' and a clear button (X).
- * Subject ID:** A text input field containing 'TEST'.
- * Confirm Subject ID:** A text input field containing 'TEST'.
- * Organization:** A dropdown menu with 'Iowa' selected and a clear button (X).
- * Course/Cycle/Intervention:** A dropdown menu with a list of options including 'Southwest Iowa Surgical Associates PC, Council Bluffs, IA (IA010)', 'VA Central Iowa Healthcare System, Des Moines, IA (IA006)', 'University of Iowa Hospitals and Clinics, Iowa City, IA (IA018)', 'Physicians' Clinic of Iowa PC, Cedar Rapids, IA (IA066)', 'Mercy Medical Center - North Iowa, Mason City, IA (IA027)', 'Medical Associates of Clinton Iowa PLC-Main Campus, Clinton, IA (IA093)', and 'VA Medical Center - University of Iowa, Iowa City, IA (IA021)'.

A green 'Continue' button with a right-pointing arrow is located at the bottom right of the form area. The footer of the page includes links for 'CONTACT US', 'PRIVACY NOTICE', 'DISCLAIMER', 'ACCESSIBILITY', and 'APPLICATION SUPPORT', along with logos for the National Cancer Institute, the Department of Health and Human Services, and USA.gov.

Pre-submission Evaluation (continued)

Step 2a: Enter the adverse event verbatim term

National Cancer Institute
at the National Institutes of Health | www.cancer.gov

CTEP AERS
CANCER THERAPY EVALUATION PROGRAM ADVERSE EVENT REPORTING SYSTEM

Help
Adverse Events

Report Adverse Events | Manage Reports

1. Study, Subject & Course/Cycle > **2. Adverse Events** > 3. Review and Report

Subject TEST
Study (A031203) Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Sup...
Course/Cycle/ Intervention ARM A (Cycle=6 weeks
XL184 (Cabozantinib): 60mg PO QD
)

Adverse Events ?

Instructions Enter the verbatim. [View CTCAE v4.0](#)

* Enter verbatim

CONTACT US | PRIVACY NOTICE | DISCLAIMER | ACCESSIBILITY | APPLICATION SUPPORT

Verbatim

- Verbatim = what the patient said to describe the adverse event
 - Examples:
 - I threw up a bunch.
 - I'm very tired.
 - My chest hurts.
 - I went to the bathroom 10 times yesterday.
- What if there is no verbatim?
 - Use the CTCAE term or your own language
 - Examples
 - Laboratory reports
 - Patient unconscious
 - Secondhand SAE report

Pre-submission Evaluation (continued)

Step 2b: Enter the adverse event CTCAE term, grade, hospitalization status, dates and outcome(s)

CTCAE AERS
Great Teams. Excellent Patients. National Cancer Institute.

Report Adverse Events | Manage Reports | Adverse Events

1. Study, Subject & Course Cycle > **2. Adverse Events** > 3. Review and Report

Subject TEST
Study (A031203) Randomized Phase II Study Comparing Cabozantinib (NSC #761966 and IND #116059) with Commercial...
Course; Cycle RM A (Cycle=6 weeks<ER>XL184 (Cabozantinib); 60mg PO QD <ER>)
Intervention

Adverse Events [View CTCAE v4.0](#)

Instructions: Enter the verbatim. [View CTCAE v4.0](#)

* Enter

Verbatim: Threw up a bunch

Verbatim Threw up a bunch

* **CTCAE Term**

* **Grade**

- 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
- 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.
- 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
- 4: Life-threatening consequences; urgent intervention indicated.
- 5: Death related to AE.

Start date (mm/dd/yyyy) **End date** (mm/dd/yyyy)

Did AE cause hospitalization?

Outcomes

- Death
- Hospitalization - Initial or prolonged
- Life-threatening
- Disability or Permanent Damage
- Congenital Anomaly / Birth Defect
- Required Intervention to Prevent Permanent Impairment / Damage (Devices)
- Other Serious (Important Medical Events)

Pre-submission Evaluation (continued)

Step 3: Click Save & Report to trigger the Rules Engine

The screenshot displays the CTEP AERS web interface. At the top, it shows the National Cancer Institute logo and the text "CTEP AERS". Below this, there are navigation tabs for "Report Adverse Events" and "Manage Reports". The current step is "2. Adverse Events", with "1. Study, Subject & Course/Cycle" and "3. Review and Report" also visible.

The main content area contains the following information:

- Subject:** TEST
- Study:** (A021202) Randomized Phase II Study Comparing Cabozantinib (NSC #781968 and IND #116059) with Commercially Supplied...
- Course/Cycle:** ARM A (Cycle=6 weeks
XL184 (Cabozantinib): 60mg PO QD
)
- Intervention:**

The "Adverse Events" section includes instructions to enter verbatim text. A dropdown menu shows "Vomiting" selected, with a grade of "3" and the verbatim text "threw up all night". The CTCAE term is "Vomiting" and the grade is "3". The start and end dates are empty. The "Did AE cause hospitalization?" dropdown is set to "Yes".

At the bottom, there are three buttons: "Save & Back", "Save", and "Save & Report". The "Save & Report" button is circled in red.

Pre-submission Evaluation (continued)

Action Recommendation

National Cancer Institute
CTEP AERS
Cancer Therapy Evaluation Program Adverse Event Reporting System

Report Adverse Events | Manage Reports

1. Study, Subject & Course/Cycle > 2. Adverse Events > 3. Review and Report

Subject TEST
Study (A031203) Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercia...
Course/Cycle/ARM A (Cycle=6 weeks
XL184 (Cabozantinib): 60mg PO QD
)

Intervention

An action is recommended.
Possible exceptions (please consult your protocol for specific expedited reporting requirements):

- Commercial agent only studies
- Studies utilizing one of the legacy AE Reporting tables (those that incorporate expectancies and attribution into the table)
- Adverse events that occurred more than 10 days after the last administration of investigational agent; intervention

Vomiting: threw up all night . Grade: 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.

Recommended Actions
Based on the data you have entered and the rules enabled for this study, the following action is recommended: [Override](#)

Select	Action	Report	Status	Due
<input type="checkbox"/>	CREATE	CTEP Expedited Report	Not started	Due in 10 days

Adverse Events

Select	Expedited Reporting Required?	Adverse Event Term	Grade	Start date	*Primary?
<input checked="" type="checkbox"/>	Yes	Vomiting: threw up all night New	3: >=6 episodes (separated by 5 minutes) in 24 hrs; tube feeding, TPN or hospitalization indicated	<input type="text"/> (mm/dd/yyyy)	<input type="checkbox"/>

When you press the Report button, you will initiate the following actions:

- CREATE CTEP Expedited Report

Report →

← Back

Pre-submission Evaluation (continued)

No Action Recommendation

The screenshot displays the CTCAE AERS (Common Terminology Criteria for Adverse Events Adverse Event Reporting System) interface. The page is titled "CTCAE AERS" and includes the National Cancer Institute logo. The user is in the "Review and Report" stage of the process. The subject is "TEST" and the study is "Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercial...". The adverse event is "Vomiting: threw up all night, Grade: 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL." The system has determined that no action is recommended based on the data entered and the rules enabled for this study. A red octagonal icon with a white hand symbol is shown next to the message. Below the message, there is a list of possible exceptions for expedited reporting requirements. The "Available Actions" section indicates that expedited reporting is not required, but an "Override" option is available. The "Adverse Events" table shows the current report with a "No" in the "Expedited Reporting Required?" column. A "Report" button is visible at the bottom right of the table area.

National Cancer Institute

CTCAE AERS

Report Adverse Events Manage Reports

1. Study, Subject & Course/Cycle > 2. Adverse Events > 3. Review and Report

Subject TEST
Study (A031203) Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercial...
Course/Cycle/ARM A (Cycle=6 weeks
XL184 (Cabozantinib): 60mg PO QD
)

Intervention

An action is NOT recommended.
Based on the data you have entered and the rules enabled for this study, **expedited reporting is not required.**

Possible exceptions (please consult your protocol for specific expedited reporting requirements):

- Commercial agent only studies
- Studies utilizing one of the legacy AE Reporting tables (those that incorporate expectedness and attribution into the table)
- Adverse events that occurred more than 90 days after the last administration of investigational agent: Intervention

Vomiting: threw up all night , Grade: 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.

Available Actions

Based on the data you have entered and the rules enabled for this study, expedited reporting is not required. If you believe expedited reporting is warranted, click 'Override' and select the report you wish to complete.

Adverse Events

Select	Expedited Reporting Required?	Adverse Event Term	Grade	Start date	*Primary?
<input checked="" type="checkbox"/>	No	Vomiting: threw up all night <New>	2: 3 - 5 episodes (separated by 5 minutes) in 24 hrs	<input type="text"/> (mm/dd/yyyy)	*

Please select a report.

Report

Back

CONTACT US PRIVACY NOTICE DISCLAIMER ACCESSIBILITY APPLICATION SUPPORT

70%

Pre-submission Evaluation (continued)

Limitations

- ‘Late’ AEs (AE’s that occur >30 days after the administration of the investigational agent)
- Protocol uses the old AE tables
- Protocols uses non-CTCAE terms to describe reporting exceptions
 - Example: Protocol states, “Do not use expedited reporting for all hematological AEs grade 3 or below.”
- Some Commercial Agent only or non-CTEP IND studies
- Currently only encompasses **exceptions** to expedited reporting

Your protocol is always the correct source of truth for expedited reporting. If CTEP-AERS differs, the protocol wins. Always double check your protocol to ensure you are reporting correctly.

Pre-submission Evaluation (continued)

'New' AE Table

Late Phase 2 and Phase 3 Studies: Expedited Reporting Requirements for Adverse Events that Occur on Studies under an IND/IDE within 30 Days of the Last Administration of the Investigational Agent/Intervention^{1,2}

FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)				
<p>NOTE: Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 312.64)</p> <p>An adverse event is considered serious if it results in ANY of the following outcomes:</p> <ol style="list-style-type: none"> 1) Death 2) A life-threatening adverse event 3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization for ≥ 24 hours 4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions 5) A congenital anomaly/birth defect. 6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6). 				
<p>ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the NCI via AdEERS within the timeframes detailed in the table below.</p>				
Hospitalization	Grade 1 Timeframes	Grade 2 Timeframes	Grade 3 Timeframes	Grade 4 & 5 Timeframes
Resulting in Hospitalization ≥ 24 hrs	10 Calendar Days			24-Hour 5 Calendar Days
Not resulting in Hospitalization ≥ 24 hrs	Not required	10 Calendar Days		
<p>NOTE: Protocol-specific exceptions to expedited reporting of serious adverse events are found in the Specific Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR</p> <p>Expedited AE reporting timelines are defined as:</p> <ul style="list-style-type: none"> o "24-Hour; 5 Calendar Days" - The AE must initially be reported via AdEERS within 24 hours of learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report. o "10 Calendar Days" - A complete expedited report on the AE must be submitted within 10 calendar days of learning of the AE. 				
<p>¹Serious adverse events that occur more than 30 days after the last administration of investigational agent/intervention and have an attribution of possible, probable, or definite require reporting as follows: Expedited 24-hour notification followed by complete report within 5 calendar days for:</p> <ul style="list-style-type: none"> • All Grade 4, and Grade 5 AEs <p>Expedited 10 calendar day reports for:</p> <ul style="list-style-type: none"> • Grade 2 adverse events resulting in hospitalization or prolongation of hospitalization • Grade 3 adverse events <p>² For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive half-lives, rounded UP to the nearest whole day, after the agent/intervention was last administered. Footnote *1* above applies after this reporting period.</p>				
Effective Date: May 5, 2011				

'Old' AE Table

Legacy Table D: Reporting Requirements for Adverse Events that occur within 30 Days¹ of the Last Dose of the Investigational Agent on Phase 2 and 3 Studies

	1	2	2	3		3		4 & 5	4 & 5 ²
	Unexpected and Expected	Unexpected	Expected	Unexpected		Expected		Unexpected	Expected
				With hospitalization	Without hospitalization	With hospitalization	Without hospitalization		
Unrelated Unlikely	Not Required	Not Required	Not Required	10 Calendar Days	Not Required	10 Calendar Days	Not required	10 Calendar Days	10 Calendar Days
Possible Probable Definite	Not Required	10 Calendar Days	Not Required	10 Calendar Days	10 Calendar Days	10 Calendar Days	Not required	24-Hour; 5 Calendar Days	10 Calendar Days
<p>¹AEs with attribution of, possible, probable, or definite that occur greater than 30 days after the last treatment with an agent/intervention under an NCI IND require reporting as follows: AdEERS 24-hour notification followed by complete report within 5 calendar days for:</p> <ul style="list-style-type: none"> • Grade 4 and Grade 5 unexpected AEs • AdEERS 10 calendar day report: • Grade 3 unexpected AEs with hospitalization or prolongation of hospitalization • Grade 5 expected AEs <p>²Although an AdEERS 24-hour notification is not required for death clearly related to progressive disease, a full report is required as outlined in the table.</p>									

Pre-submission Evaluation (continued)

Override

National Cancer Institute www.cancer.gov

CTEP AERS
Clinical Trial Evaluation Program Adverse Event Reporting System

Report Adverse Events | Manage Reports

1. Study, Subject & Course/Cycle > 2. Adverse Events > 3. Review and Report

Subject TEST
Study (A031203) Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercia...
Course/Cycle/ARM A (Cycle=6 weeks
XL184 (Cabozantinib): 60mg PO QD
)
Intervention

An action is NOT recommended.
Based on the data you have entered and the rules enabled for this study, **expedited reporting is not required.**
Possible exceptions (please consult your protocol for specific expedited reporting requirements):

- Commercial agent only studies
- Studies utilizing one of the legacy AE Reporting tables (those that incorporate expectedness and attribution into the table)
- Adverse events that occurred more than 10 days after the last administration of investigational agent intervention

Vomiting: threw up all night . Grade: 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.

Available Actions
Based on the data you have entered and the rules enabled for this study, expedited reporting is not required. If you believe expedited reporting is warranted, click 'Override' and select the report you wish to complete.

Adverse Events

Select	Expedited Reporting Required?	Adverse Event Term	Grade	Start date	*Primary?
<input checked="" type="checkbox"/>	No	Vomiting: threw up all night <small>New</small>	2: 3 - 5 episodes (separated by 5 minutes) in 24 hrs	<input type="text" value="mm/dd/yyyy"/>	<input type="checkbox"/>

Please select a report.

[Override](#)

CONTACT US | PRIVACY NOTICE | DISCLAIMER | ACCESSIBILITY | APPLICATION SUPPORT

70%

Recipients

Always copied on Report Submissions:

Contact info entered into CTEP-AERS during report creation	Reporter
	Submitter (often the same person as the Reporter)
	Treating Physician
	Any CCs added by the Submitter (optional)
Contact information housed at NCI (not viewed in CTEP-AERS)	Study PI
	Alliance Adverse Event Coordinators
	Others as added by Alliance Leadership
	NCI Adverse Event Notification System

Amendments to Reports

- All AdEERS Reports created since 1/1/2008 are available in CTEP-AERS and can be amended using CTEP-AERS
 - To amend a report created prior to 1/1/2008, please contact the CTEP Help Desk: ncictephelp@ctep.nci.nih.gov
- Amendments to CTEP-AERS reports or old AdEERS reports are created via the 'Manage Reports' tab on the CTEP-AERS home page
 - Study number, Subject ID, and Ticket number required for access

CTEP-AERS Resources

- CTEP-AERS Home Page
 - http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htm
 - CTEP-AERS Application: <https://eapps-ctep.nci.nih.gov/ctepaers>
- Online resources
 - Comprehensive Training Guide
 - Training Presentations
 - Recorded Training Demo
 - FAQ Document
 - Practice Application: <https://betapps-ctep.nci.nih.gov/ctepaers/public/login>
- CTEP personnel available via email or phone
 - AEMD Help Desk (formerly known as the AdEERS MD Help Desk)
 - aemd@tech-res.com
 - (301) 897-7497
 - Technical Help Desk for technical, application-related issues
 - ncictephelp@ctep.nci.nih.gov
 - 1-888-283-7457

